This page will host Events plug-in for all Clarion and trade events.

Upcoming Events

View Calendar
Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

By: via Business Wire

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on January 10, 2022 on Savara’s website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.25
+2.28 (1.00%)
AAPL  269.00
+0.19 (0.07%)
AMD  258.01
-1.66 (-0.64%)
BAC  52.87
-0.15 (-0.28%)
GOOG  268.43
-1.50 (-0.56%)
META  751.44
+0.62 (0.08%)
MSFT  542.07
+10.55 (1.98%)
NVDA  201.03
+9.54 (4.98%)
ORCL  280.83
-0.57 (-0.20%)
TSLA  460.55
+8.13 (1.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.